HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

deoxynybomycin

structure

Also Known As:

6,8,11-trimethyl-2H,4H-oxazolo(5,4,3-IJ)pyrido(3,2-g)quinoline-4,10(11H)-dione

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        deoxynybomycin: 1

Experts

1.	Egawa, K: 1 article (09/2000)
2.	Kunimoto, S: 1 article (09/2000)
3.	Nos, K: 1 article (09/2000)
4.	Nosaka, C: 1 article (09/2000)
5.	Takeuchi, T: 1 article (09/2000)
6.	Yamori, T: 1 article (09/2000)

Related Diseases

1.	Stomach Neoplasms (Stomach Cancer) 09/01/2000 - "Deoxynybomycin selectively inhibited growth of human osteoblastic sarcoma Saos-2, gastric cancer TMK-1, and monocytic leukemia THP-1 cells, but did not affect survival of normal human fibroblasts at doses up to 5 microg/ml. Results from an assay system using a panel of 39 human cancer cell lines indicated that deoxynybomycin has selective cytotoxic activity against lung carcinoma cell lines. "
2.	Sarcoma (Soft Tissue Sarcoma) 09/01/2000 - "Deoxynybomycin selectively inhibited growth of human osteoblastic sarcoma Saos-2, gastric cancer TMK-1, and monocytic leukemia THP-1 cells, but did not affect survival of normal human fibroblasts at doses up to 5 microg/ml. Results from an assay system using a panel of 39 human cancer cell lines indicated that deoxynybomycin has selective cytotoxic activity against lung carcinoma cell lines. "
3.	Neoplasms (Cancer) 09/01/2000 - "Deoxynybomycin is a selective anti-tumor agent inducing apoptosis and inhibiting topoisomerase I." 09/01/2000 - "Deoxynybomycin selectively inhibited growth of human osteoblastic sarcoma Saos-2, gastric cancer TMK-1, and monocytic leukemia THP-1 cells, but did not affect survival of normal human fibroblasts at doses up to 5 microg/ml. Results from an assay system using a panel of 39 human cancer cell lines indicated that deoxynybomycin has selective cytotoxic activity against lung carcinoma cell lines. " 09/01/2000 - "It inhibited topoisomerase I but not topoisomerase II. These results suggest that deoxynybomycin may be useful in cancer chemotherapy."
4.	Leukemia 09/01/2000 - "Deoxynybomycin selectively inhibited growth of human osteoblastic sarcoma Saos-2, gastric cancer TMK-1, and monocytic leukemia THP-1 cells, but did not affect survival of normal human fibroblasts at doses up to 5 microg/ml. Results from an assay system using a panel of 39 human cancer cell lines indicated that deoxynybomycin has selective cytotoxic activity against lung carcinoma cell lines. "
5.	Carcinoma (Carcinomatosis) 09/01/2000 - "Deoxynybomycin selectively inhibited growth of human osteoblastic sarcoma Saos-2, gastric cancer TMK-1, and monocytic leukemia THP-1 cells, but did not affect survival of normal human fibroblasts at doses up to 5 microg/ml. Results from an assay system using a panel of 39 human cancer cell lines indicated that deoxynybomycin has selective cytotoxic activity against lung carcinoma cell lines. "

Related Drugs and Biologics

1.	Type I DNA Topoisomerases (Topoisomerase I)
2.	Type II DNA Topoisomerases (Topoisomerase II)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)